These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 11589080)

  • 1. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
    Soto Alvarez J; González Vilchez F
    An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
    Alvarez JS; Vílchez FG
    Rev Esp Cardiol; 2001 Feb; 54(2):175-80. PubMed ID: 11181306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of bisoprolol treatment for heart failure.
    Di Stasi F; Scalone L; De Portu S; Menditto E; Mantovani LG
    Ital Heart J; 2005 Dec; 6(12):950-5. PubMed ID: 16502708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone in left-sided heart failure: how does it fit in?
    Margo KL; Luttermoser G; Shaughnessy AF
    Am Fam Physician; 2001 Oct; 64(8):1393-8. PubMed ID: 11681781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The significance of aldosterone in chronic heart failure: the RALES study].
    Simko F; Bada V; Simková M; Simko J; Kovács L; Hulín I
    Vnitr Lek; 2002 Aug; 48(8):767-72. PubMed ID: 12425209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure disease management programs: a cost-effectiveness analysis.
    Chan DC; Heidenreich PA; Weinstein MC; Fonarow GC
    Am Heart J; 2008 Feb; 155(2):332-8. PubMed ID: 18215605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
    Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
    Gao X; Peng L; Adhikari CM; Lin J; Zuo Z
    J Card Fail; 2007 Apr; 13(3):170-7. PubMed ID: 17448413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
    Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure.
    Galbreath AD; Krasuski RA; Smith B; Stajduhar KC; Kwan MD; Ellis R; Freeman GL
    Circulation; 2004 Dec; 110(23):3518-26. PubMed ID: 15531765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of bisoprolol in chronic heart failure].
    Ekman M; Zethraeus N; Dahlström U; Höglund C
    Lakartidningen; 2002 Feb; 99(7):646-50. PubMed ID: 11887711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is B-type natriuretic peptide-guided heart failure management cost-effective?
    Morimoto T; Hayashino Y; Shimbo T; Izumi T; Fukui T
    Int J Cardiol; 2004 Aug; 96(2):177-81. PubMed ID: 15262031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure.
    Feola M; Menardi E; Ribichini F; Vado A; Deorsola A; Ferrero V; Visconti G; Milanese U; Uslenghi E
    Med Sci Monit; 2003 Aug; 9(8):CR341-5. PubMed ID: 12942029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II].
    Lévy P; Mérot JL; Lechat P; Lévy E; Bogillot O
    Therapie; 2001; 56(4):421-5. PubMed ID: 11677866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.